At least one peer-reviewed publication or major-journal commentary by 2027-06-24 criticizes psychedelic indication expansion for outpacing durability and mechanistic evidence.

By mid-2027, at least one serious scientific journal will publish a prominent critique arguing that enthusiasm for psychedelics as treatments has raced ahead of the actual evidence. Researchers will point out that most studies are small, short-term, and don't prove that benefits last. This matters because overpromising can mislead patients, distort investment decisions, and ultimately set the field back if results don't hold up.

Small trials and case reports proliferate without long-term follow-up. The methodological gap between the neuroplasticity narrative and durable outcomes will draw documented scientific critique.